

Developing A Novel Topical Treatment for Atopic Dermatitis



Our focus is on TIR-C – an immunomodulatory, water-based cream for treatment of mild-moderate Atopic Dermatitis (AD). With promising results in vitro and in several animal models, we are ready to bring TIR-C to pre-regulatory trials.

Problem

- 1 in 5 children and 1 in 10 adults in Sweden suffer from AD
- 7% of Europeans and 9% of US citizens
- Triggers asthma development in children
- 2B EUR annually in productivity losses due to AD in the EU
- Burden on patients' quality of life

Solution

- Non-coding synthetic single-stranded oligonucleotide
- Acts on cell surface
- Inhibits uptake of ligands activating endosomal toll-like receptors (TLR3,4,7)

Market

- 51B SEK globally with 7% CAGR
- Growth driven by excessive cleanliness, indoors lifestyles and pollution

Competitors

- Corticosteroids
- JAK inhibitors
- Biologicals

Competitive Advantages

- Suitable for pediatric use
- Low risk of side effects
- Affordable
- Easy administration
- Long-lasting effects

Business Model

- Upon successful completion of phase IIa license API to large pharma for subsequent clinical trials, registration and marketing.

Patent

- Approved patents in Europe, USA, Australia and with more pending

✓ Key Milestones So Far

- Confirmed effect in vitro
- Successful inhibition of TLR3-mediated responses in macaques
- Confirmed anti-itch effects in mice
- Established formulation of cream
- Promising results from pilot dog study with natural AD
- Confirmed permeability of topical treatment in human skin explants



Leo Holmgren
CEO



Prof. Anna-Lena Spetz
Founder & CSO



Assoc. Prof. Jan-Erik Nyström
Chairman

Funding Need

- 25M SEK (€2.5M)

Key Milestones Ahead

- Results from large efficacy study in dogs
- Bioanalytical method development in organ samples
- GLP & Clinical material GMP production development
- Toxicity trials